Why Is ALNYLAM PHARMACEUTIC (ALNY) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 2, 2026 at 11:29 AM ET · reviewed against 3 wire stories
ALNYLAM PHARMACEUTIC (ALNY) is drawing unusual attention today. Our newswire has captured 3 stories on ALNY across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ALNY stock is up 7.67% at $264.98 as of the latest trade, driven by renewed investor interest in the company’s drug development pipeline and a reiteration of a positive analyst rating. The stock has surged from an opening price of $246.51 to a session high of $267.22, with volume reaching 0.7 million shares, more than half of its 3-month daily average. The move follows recent updates on clinical data and a webcast announcement for investor conferences.
What Happened
Alnylam Pharmaceuticals is set to present new clinical and real-world data at the 2026 ESC Congress, focusing on its transthyretin-mediated amyloidosis and hypertension programs. This comes alongside the company’s announcement of a webcast for investor conferences in September, which has drawn attention to its long-term strategic outlook. H.C. Wainwright reiterates its Buy rating for ALNY, citing the company’s drug differentiation and maintaining a $455 price target. These developments have contributed to a positive sentiment among investors, particularly in light of the recent AMVUTTRA results and a new RNAi approach for treating high blood pressure.
What The Data Shows
The stock has traded between $197.81 and $495.55 over the past 52 weeks and is currently trading near the upper end of that range. With a market cap of $32.2 billion and a P/E ratio of 43.8, Alnylam is positioned as a high-growth biotech firm. Revenue has grown 95.1% in the trailing twelve months, and the company maintains a net margin of 16.1%. The stock has also printed 15 fresh 52-week highs on September 2, 2026. Over the last eight sessions, the stock has risen 0.8% from $236.22 to $238.16, showing a gradual upward trend. Volume has been elevated, though not at extreme levels.
What To Watch
The company has not announced an upcoming earnings date. Investors should monitor the breadth of coverage and any further analyst commentary following the webcast presentations at the September investor conferences.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ALNY · Sep 2 session (5-min) · +8.65% vs prior close · updated 8:45 PM ETAI sentiment, last 36h · averaged over 3 stories · 54/100 neutral
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
10h agoGuruFocusNEUTRAL 50Earnings
Alnylam Pharmaceuticals (ALNY) Set to Report Q3 Earnings Amid Mixed Analyst Forecasts
On October 28, 2026, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is preparing to release its third-quarter earnings report before the market opens on October 29.
11h agoSeeking AlphaNEUTRAL 50Earnings
Alnylam Pharmaceuticals Q3 2026 Earnings Preview
Alnylam Pharmaceuticals (ALNY) is scheduled to announce Q3 earnings results on Thursday, October 29th, before market open. The consensus EPS Estimate is $2.25 (
Alnylam stock maintained at Buy by H.C. Wainwright on HD data
Alnylam stock maintained at Buy by H.C. Wainwright on HD data
Frequently asked questions
Why is ALNY stock moving today?
ALNYLAM PHARMACEUTIC (ALNY) is drawing unusual attention today. Our newswire has captured 3 stories on ALNY across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100). The most recent driver: "Alnylam Pharmaceuticals (ALNY) Set to Report Q3 Earnings Amid Mixed Analyst Forecasts" (GuruFocus).
Is ALNY a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ALNY coverage reads 54/100 over 3 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →